Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bone-Metastatic, Castration-Resistant Prostate Cancer”

107 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 107 results

Large-scale testing (Phase 3)Study completedNCT00134056
What this trial is testing

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Who this might be right for
Metastatic CancerProstate Cancer
SWOG Cancer Research Network 1,038
Testing effectiveness (Phase 2)Active Not RecruitingNCT03217747
What this trial is testing

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmCastration-Resistant Prostate CarcinomaMalignant Solid Neoplasm+7 more
M.D. Anderson Cancer Center 173
Testing effectiveness (Phase 2)Ended earlyNCT04616547
What this trial is testing

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate Adenocarcinoma+3 more
National Cancer Institute (NCI) 1
Not applicableStudy completedNCT02981797
What this trial is testing

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Who this might be right for
Prostate CancerProstate Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute 10
Not applicableStudy completedNCT01812668
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Barbara Ann Karmanos Cancer Institute 20
Early research (Phase 1)WithdrawnNCT02396368
What this trial is testing

Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate CancerBone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Not applicableLooking for participantsNCT04693377
What this trial is testing

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the Bone+15 more
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT01106352
What this trial is testing

Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Bone MetastasesCastration-Resistant Prostate Cancer
Bayer 70
Early research (Phase 1)Study completedNCT03076203
What this trial is testing

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Who this might be right for
Prostate Carcinoma Metastatic to the BoneStage IV Prostate AdenocarcinomaHormone-refractory Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 14
Testing effectiveness (Phase 2)Study completedNCT02598895
What this trial is testing

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
University of Washington 14
Not applicableUnknownNCT05078151
What this trial is testing

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Vall d'Hebron Institute of Oncology 69
Post-approval studies (Phase 4)Study completedNCT02721433
What this trial is testing

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Who this might be right for
Breast CancerProstate CancerMetastasis
Ottawa Hospital Research Institute 263
Not applicableStudy completedNCT01833208
What this trial is testing

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneRecurrent Prostate Carcinoma+1 more
Roswell Park Cancer Institute 15
Not applicableLooking for participantsNCT06529549
What this trial is testing

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Study completedNCT02601014
What this trial is testing

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Who this might be right for
Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 32
Testing effectiveness (Phase 2)UnknownNCT04033432
What this trial is testing

SEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents+7 more
Northwestern University 14
Testing effectiveness (Phase 2)Study completedNCT01650194
What this trial is testing

Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Global Development, Inc. 60
Testing effectiveness (Phase 2)WithdrawnNCT02420587
What this trial is testing

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)WithdrawnNCT00691899
What this trial is testing

Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Who this might be right for
Prostate Cancer
Merck Sharp & Dohme LLC
Next Page